C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2017’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory under development targeting C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AFFiRiS AG

ChemoCentryx Inc

Dompe Farmaceutici SpA

Novo Nordisk A/S

Prommune Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Companies Involved in Therapeutics Development 20

AFFiRiS AG 20

ChemoCentryx Inc 20

Dompe Farmaceutici SpA 21

Novo Nordisk A/S 21

Prommune Inc 22

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drug Profiles 23

ALS-205 Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

avacopan Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DF-2593A Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Drug to Antagonize C5aR for Periodontitis Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-67 Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody to Antagonize C5aR for Rheumatoid Arthritis and Lewis Lung Cancer Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Vaccine to Target C5a for Alzheimer's Disease Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Dormant Products 36

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Discontinued Products 37

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Product Development Milestones 38

Featured News & Press Releases 38

Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan 38

May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 38

Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 39

Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan 39

Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’) 41

Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 42

Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 42

Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 44

Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 44

Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 46

May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 47

Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 49

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 49

Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 50

Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by AFFiRiS AG, H2 2017 20

Pipeline by ChemoCentryx Inc, H2 2017 20

Pipeline by Dompe Farmaceutici SpA, H2 2017 21

Pipeline by Novo Nordisk A/S, H2 2017 21

Pipeline by Prommune Inc, H2 2017 22

Dormant Projects, H2 2017 36

Discontinued Products, H2 2017 37

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administrations, H2 2017 17

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports